← Leaderboards
Melissa J Robbiani
Tulane University Of Louisiana
$27,757,591
Attributed
$29,152,982
Total exposure
58
Grants
41
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–13$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$34,334,973 · 59
By mechanism
R01$14,142,665 · 5
U19$8,908,765 · 5
R37$6,362,833 · 1
P51$2,628,097 · 41
R21$2,292,613 · 5
P01$0 · 2
Top collaborators
- Alexandra Trkola4 shared
- Thomas Michael Zydowsky2 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Ronald S. Veazey$44,796,137
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsInfectionMacacaVirusAnimalsPreventCellsHiv InfectionsIn VitroResearch PersonnelIn VivoGrantResourcesSourceVaginaUnited States National Institutes Of HealthFundingMicrobicideResponseMacaca MulattaBaseSimian Immunodeficiency VirusPathogenCytokine
Grant awards (112)
Modulating mucosal DCs and T cells to limit SIV spread$852,648
R37 · FY2013 · AI · contact PI
A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy$194,226
R21 · FY2013 · AI
Modulating mucosal DCs and T cells to limit SIV spread$907,071
R37 · FY2012 · AI · contact PI
HIV-envelope-specific DARPin-based microbicide strategies$694,352
R01 · FY2012 · AI · contact PI
A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy$230,503
R21 · FY2012 · AI
HIV-envelope-specific DARPin-based microbicide strategies$745,303
R01 · FY2011 · AI · contact PI
Modulating mucosal DCs and T cells to limit SIV spread$732,071
R37 · FY2011 · AI · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$57,750
P51 · FY2011 · RR · contact PI
HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE$57,750
P51 · FY2011 · RR · contact PI
IMPACT OF ART ON DC & TREG RESPONSES$57,750
P51 · FY2011 · RR · contact PI
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS$57,750
P51 · FY2011 · RR · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$57,750
P51 · FY2011 · RR · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$57,750
P51 · FY2011 · RR · contact PI
Modulating mucosal DCs and T cells to limit SIV spread$934,218
R37 · FY2010 · AI · contact PI
ZCM: A novel broad-spectrum microbicide for STIs$746,027
U19 · FY2010 · AI · contact PI
Topical tactics to limit HIV/HSV spread by mucosal DCs$746,027
U19 · FY2010 · AI · contact PI
HIV-envelope-specific DARPin-based microbicide strategies$438,045
R01 · FY2010 · AI · contact PI
Impact of ART on DC and Teg Responses in Oral Tissues$404,449
R01 · FY2010 · DE · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$61,801
P51 · FY2010 · RR · contact PI
HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE$61,801
P51 · FY2010 · RR · contact PI
IMPACT OF ART ON DC & TREG RESPONSES$61,801
P51 · FY2010 · RR · contact PI
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS$61,801
P51 · FY2010 · RR · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$61,801
P51 · FY2010 · RR · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$61,801
P51 · FY2010 · RR · contact PI
ZCM: A novel broad-spectrum microbicide for STIs$1,082,520
U19 · FY2009 · AI · contact PI
Modulating mucosal DCs and T cells to limit SIV spread$987,500
R37 · FY2009 · AI · contact PI
Impact of ART on DC and Teg Responses in Oral Tissues$610,937
R01 · FY2009 · DE · contact PI
HIV-envelope-specific DARPin-based microbicide strategies$488,354
R01 · FY2009 · AI · contact PI
P2 - Topical tactics to limit HIV/HSV spread by mucosal DCs$347,979
U19 · FY2009 · AI · contact PI
Core A - Administrative$72,110
U19 · FY2009 · AI · contact PI
IMPACT OF ART ON DC & TREG RESPONSES$58,149
P51 · FY2009 · RR · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$58,149
P51 · FY2009 · RR · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$58,149
P51 · FY2009 · RR · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$58,149
P51 · FY2009 · RR · contact PI
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS$36,333
P51 · FY2009 · RR · contact PI
ZCM: A novel broad-spectrum microbicide for STIs$1,106,652
U19 · FY2008 · AI · contact PI
Modulating mucosal DCs and T cells to limit SIV spread$938,409
R37 · FY2008 · AI · contact PI
Impact of ART on DC and Teg Responses in Oral Tissues$632,205
R01 · FY2008 · DE · contact PI
P2 - Topical tactics to limit HIV/HSV spread by mucosal DCs$548,949
U19 · FY2008 · AI · contact PI
ISS-ODN activation of tonsillar APCs to augment immunity$478,538
R01 · FY2008 · DE · contact PI
Core A - Administrative$64,930
U19 · FY2008 · AI · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$63,253
P51 · FY2008 · RR · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$63,253
P51 · FY2008 · RR · contact PI
ESTABLISHING MUCOSAL CANDIDA INFECTIONS IN MACAQUES$63,253
P51 · FY2008 · RR · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$63,253
P51 · FY2008 · RR · contact PI
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS$37,169
P51 · FY2008 · RR · contact PI
ZCM: A novel broad-spectrum microbicide for STIs$1,102,282
U19 · FY2007 · AI · contact PI
Modulating mucosal DCs and T cells to limit SIV spread$1,010,916
R37 · FY2007 · AI · contact PI
P2 - Topical tactics to limit HIV/HSV spread by mucosal DCs$535,575
U19 · FY2007 · AI · contact PI
Impact of ART on DC and Teg Responses in Oral Tissues$514,174
R01 · FY2007 · DE · contact PI
ISS-ODN activation of tonsillar APCs to augment immunity$513,132
R01 · FY2007 · DE · contact PI
Assessment of AFE inhibitors in dendritic cell-T cell mixtures$254,890
U19 · FY2007 · AI · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$71,639
P51 · FY2007 · RR · contact PI
ESTABLISHING MUCOSAL CANDIDA INFECTIONS IN MACAQUES$71,639
P51 · FY2007 · RR · contact PI
HSV-2/SHIV VAGINAL INFECTION MODEL FOR MICROBICIDES$71,638
P51 · FY2007 · RR · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$71,638
P51 · FY2007 · RR · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$71,638
P51 · FY2007 · RR · contact PI
Core A - Administrative$64,514
U19 · FY2007 · AI · contact PI
ZCM: A novel broad-spectrum microbicide for STIs$1,144,510
U19 · FY2006 · AI · contact PI
ISS-ODN activation of tonsillar APCs to augment immunity$892,001
R01 · FY2006 · DE · contact PI
The Mucosal Dendritic Cell T Milieu and SIV Spread$780,056
R01 · FY2006 · AI · contact PI
Dendritic cell defensin and type I IFN responses in HIV$531,887
R01 · FY2006 · DE · contact PI
P2 - Topical tactics to limit HIV/HSV spread by mucosal DCs$470,534
U19 · FY2006 · AI · contact PI
ASSESSMENT OF AFE INHIBITORS IN DC-T CELL MIXTURES$238,967
U19 · FY2006 · AI · contact PI
ISS-ODN activation of tonsillar APCs to augment immunity$140,518
R01 · FY2006 · DE · contact PI
Core A - Administrative$131,506
U19 · FY2006 · AI · contact PI
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$65,435
P51 · FY2006 · RR · contact PI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$65,435
P51 · FY2006 · RR · contact PI
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$65,435
P51 · FY2006 · RR · contact PI
AT-2 SIV VACCINATION AFTER DENDRITIC CELL MOBILIZATION$65,435
P51 · FY2006 · RR · contact PI
HSV-2/SHIV VAGINAL INFECTION MODEL FOR MICROBICIDES$28,846
P51 · FY2006 · RR · contact PI
The Mucosal Dendritic Cell T Milieu and SIV Spread$782,673
R01 · FY2005 · AI
ISS-ODN activation of tonsillar APCs to augment immunity$663,123
R01 · FY2005 · DE
Dendritic cell defensin and type I IFN responses in HIV$528,696
R01 · FY2005 · DE
ASSESSMENT OF AFE INHIBITORS IN DC-T CELL MIXTURES$250,793
U19 · FY2005 · AI
Mucosal innate and adaptive responses during infection$231,420
R21 · FY2005 · DE
Boosting PDC and B cell activity to drive SIV immunity$231,420
R21 · FY2005 · AI
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY$54,510
P51 · FY2005 · RR
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$54,500
P51 · FY2005 · RR
AT-2 SIV VACCINATION AFTER DENDRITIC CELL MOBILIZATION$54,500
P51 · FY2005 · RR
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$52,511
P51 · FY2005 · RR
HSV-2/SHIV VAGINAL INFECTION MODEL FOR MICROBICIDES$52,113
P51 · FY2005 · RR
The Mucosal Dendritic Cell T Milieu and SIV Spread$766,992
R01 · FY2004 · AI
ISS-ODN activation of tonsillar APCs to augment immunity$672,258
R01 · FY2004 · DE
Dendritic cell defensin and type I IFN responses in HIV$517,395
R01 · FY2004 · DE
Mucosal innate and adaptive responses during infection$231,420
R21 · FY2004 · DE
Boosting PDC and B cell activity to drive SIV immunity$231,420
R21 · FY2004 · AI
BLOCKING VIRUS SPREAD WITH CARRAGEENAN-BASED COMPOUNDS$47,161
P51 · FY2004 · RR
AT-2 SIV VACCINATION AFTER DENDRITIC CELL MOBILIZATION$47,161
P51 · FY2004 · RR
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$47,161
P51 · FY2004 · RR
The Mucosal Dendritic Cell T Milieu and SIV Spread$751,768
R01 · FY2003 · AI
Dendritic cell defensin and type I IFN responses in HIV$520,051
R01 · FY2003 · DE
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD$61,544
P51 · FY2003 · RR
AT-2 SIV VACCINATION AFTER DENDRITIC CELL MOBILIZATION$61,544
P51 · FY2003 · RR
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS$61,544
P51 · FY2003 · RR
The Mucosal Dendritic Cell T Milieu and SIV Spread$736,985
R01 · FY2002 · AI
SIV Capture, Retention, and Spread by Dendritic Cells$245,727
R21 · FY2002 · AI
MUCOSAL LEUKOCYTES IN SIV PATHOGENESIS: DENDRITIC CELLS$0
P51 · FY2002 · RR
Assessing fusion/entry inhibitors in DC-T cell mixtures$0
P01 · FY2002 · AI
BLOCKING DENDRITIC HIV/SIV BY CARRAGEENAN MICROBICIDES$0
P01 · FY2002 · HD
Assessing fusion/entry inhibitors in DC-T cell mixtures$0
P01 · FY2002 · AI
SIV Capture, Retention, and Spread by Dendritic Cells$245,727
R21 · FY2001 · AI
PRESENTATION OF INACTIVATED SIV BY DENDRITIC CELLS$147,378
R21 · FY2001 · AI
PRESENTATION OF INACTIVATED SIV BY DENDRITIC CELLS$69,622
R21 · FY2001 · AI
BLOCKING DENDRITIC HIV/SIV BY CARRAGEENAN MICROBICIDES$0
P01 · FY2001 · HD
MUCOSAL LEUKOCYTES IN SIV PATHOGENESIS: DENDRITIC CELLS$0
P51 · FY2001 · RR
Assessing fusion/entry inhibitors in DC-T cell mixtures$0
P01 · FY2001 · AI
MUCOSAL LEUKOCYTES AND SIV PATHOGENESIS$271,108
R01 · FY2000 · AI
PRESENTATION OF INACTIVATED SIV BY DENDRITIC CELLS$233,750
R21 · FY2000 · AI
MUCOSAL LEUKOCYTES AND SIV PATHOGENESIS$67,665
R01 · FY2000 · AI
PRESENTATION OF SIV DELTA NEF BY DENORITIC CELLS$54,327
P51 · FY2000 · RR
ROLE OF MUCOSAL LEUKOCYTES IN SIV PATHOGENESIS$54,327
P51 · FY2000 · RR